Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Chronic Kidney Diseases

In brief

Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.

Key facts

Study ID
NCT03471117
Run by
The University of Texas at Arlington
People needed
5
Starts
2018-04-01
Expected to finish
2020-01-14
Last updated by the study team
2026-07-27

Who can join

Age: 35 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.